Literature DB >> 31928593

Tofacitinib for the treatment of refractory Takayasu's arteritis: description of 2 cases.

Adalgisa Palermo1, Chiara Marvisi1, Massimiliano Casali2, Nicolò Pipitone3, Francesco Muratore3, Carlo Salvarani4.   

Abstract

Entities:  

Year:  2020        PMID： 31928593

Source DB:  PubMed          Journal:  Clin Exp Rheumatol        ISSN： 0392-856X            Impact factor:   4.473


× No keyword cloud information.
  5 in total

Review 1.  An Update on Childhood-Onset Takayasu Arteritis.

Authors:  Florence A Aeschlimann; Rae S M Yeung; Ronald M Laxer
Journal:  Front Pediatr       Date:  2022-04-13       Impact factor: 3.569

2.  Tofacitinib in patients with refractory Takayasu's arteritis.

Authors:  Jing Li; Mengtao Li; Xinping Tian; Xiaofeng Zeng
Journal:  Rheumatology (Oxford)       Date:  2020-11-01       Impact factor: 7.580

Review 3.  Contribution of Janus-Kinase/Signal Transduction Activator of Transcription Pathway in the Pathogenesis of Vasculitis: A Possible Treatment Target in the Upcoming Future.

Authors:  Roberto Bursi; Giacomo Cafaro; Carlo Perricone; Ilenia Riccucci; Santina Calvacchi; Roberto Gerli; Elena Bartoloni
Journal:  Front Pharmacol       Date:  2021-03-29       Impact factor: 5.810

Review 4.  Novel Therapies in Takayasu Arteritis.

Authors:  Francesca Regola; Martina Uzzo; Paola Toniati; Barbara Trezzi; Renato Alberto Sinico; Franco Franceschini
Journal:  Front Med (Lausanne)       Date:  2022-01-12

Review 5.  Treatment of Giant Cell Arteritis and Takayasu Arteritis-Current and Future.

Authors:  B Hellmich; A F Águeda; S Monti; R Luqmani
Journal:  Curr Rheumatol Rep       Date:  2020-10-12       Impact factor: 4.592
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.